Attig, Sebastian

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 2,488

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 1,819

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,052

Cytomegalovirus Infection: A Driving Force in Human T Cell Immunosenescence

KOCH, S., LARBI, A., ÖZCELIK, D., SOLANA, R., GOUTTEFANGEAS, C., ATTIG, S., WIKBY, A., STRINDHALL, J., FRANCESCHI, C., & PAWELEC, G. (2007) · Annals of the New York Academy of Sciences

Cytomegalovirus and herpesvirus researchHerpesvirus Infections and Treatments

Cited by 242

Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients

Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer

Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches

Cited by 70